Fundies.
English

Segment disclosures

Company overview

Arcus Biosciences, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 17 retained observations 12 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Reportable Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=rcus:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3041000000 USD20260805Open filing evidence
2026-01-01 – 2026-06-3058000000 USD20260805Open filing evidence
2026-01-01 – 2026-03-3117000000 USD20260505Open filing evidence
2025-01-01 – 2025-12-31247000000 USD20260225Open filing evidence
2025-07-01 – 2025-09-3026000000 USD20251028Open filing evidence
2025-01-01 – 2025-09-30214000000 USD20251028Open filing evidence
2025-04-01 – 2025-06-30160000000 USD20260805Open filing evidence
2025-01-01 – 2025-06-30188000000 USD20260805Open filing evidence
2025-01-01 – 2025-03-3128000000 USD20260505Open filing evidence
2024-01-01 – 2024-12-31258000000 USD20260225Open filing evidence
2024-07-01 – 2024-09-3048000000 USD20251028Open filing evidence
2024-01-01 – 2024-09-30232000000 USD20251028Open filing evidence
2024-04-01 – 2024-06-3039000000 USD20250806Open filing evidence
2024-01-01 – 2024-06-30184000000 USD20250806Open filing evidence
2024-01-01 – 2024-03-31145000000 USD20250506Open filing evidence
2023-01-01 – 2023-12-31117000000 USD20260225Open filing evidence
2022-01-01 – 2022-12-31112000000 USD20250225Open filing evidence